Dr. Tobias Schatton’s laboratory research centers on immune checkpoint pathways and homing mediators in skin cancer progression, skin disorders, and normal skin homeostasis. His objective is to mechanistically dissect how cell type-specific glycostructural modifications impact skin cancer immunobiology, normal skin physiology, therapeutic efficacy, and patient outcome. Major focuses of the Schatton laboratory include previously unrecognized cancer- versus immune cell subset-specific roles of glycoprotein receptors, such as PD-1 and Tim-3, homing molecules, and their roles in tumor immune evasion, growth, metastasis, and immunotherapy response. Dr. Schatton is the principal investigator on several NIH grants from the NCI and serves as the Co-Director of the Harvard Program of Glyco-Immunology and Oncology.
